Retrophin

Retrophin, Inc.
Investor Relations Department
12255 El Camino Real Suite 250
San Diego, CA 92130
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: RTRX	
Last Trade:	18.47
Trade Time:	4:00 PM ET Apr 21, 2017
Change:	-0.37 (-1.964%)
Day Range	18.44 - 19.05
52-Week Range	13.31 - 24.57
Volume	245,183

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and others.

Retrophin is currently enrolling patients in a potentially pivotal Phase ... (more)

Stock Performance

Press Releases [View all]

Apr 20, 2017
Retrophin to Report First Quarter 2017 Financial Results

Apr 12, 2017
Retrophin Appoints Ron Squarer to Board of Directors

Mar 23, 2017
John A. Orwin Joins Retrophin Board of Directors

Mar 7, 2017
Retrophin to Present at the Barclays Global Healthcare Conference

Mar 1, 2017
Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results

Financials [View all]

Second Quarter Financial Results

Mar 1, 2017
Annual Report (10-K)

Apr 14, 2017
Proxy Statement (DEF 14A)

Nov 4, 2016
Quarterly Report (10-Q)

Aug 5, 2016
Quarterly Report (10-Q)

May 5, 2016
Quarterly Report (10-Q)